Research Alliance Corp. II
Status: Liquidated
U=S
| IPO Proceeds, $M | $149.50M |
|---|---|
| IPO Date | Mar 18, 2021 |
| CEO | Peter Kolchinsky, Ph.D. |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Dec 2, 2022 |
| Closing Date | Dec 2, 2022 |
RACB
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Research Alliance Corp. II:
- Structure and cap table
- 6 directors & officers
- 12 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Peter Kolchinsky, Ph.D. | 44 | CEO & Chairman |
| Tess Cameron | 35 | CFO |
| Matthew Hammond, Ph.D. | 32 | CIO & Director |
| Stephen J. Hoffman, M.D., Ph.D. | 67 | Director |
| Thomas Leggett | 44 | Director |
| Clive Patience | 57 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Jefferies | BR | 13,000,000 | units |
| 13,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.